Axitinib
Generated by NIH 3D workflows using data provided by
Kzoghebi
Created:
2/17/19
Submitted:
10/6/26
Published:
10/6/26
Select an image below to view
Learn more about NIH 3D workflow outputs
Category
Description
Axitinib is an orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.
